Angiogenesis

Where the papers sit

9 papers from the last 6 months study angiogenesis directly · updated from PubMed 1 Nov 2026

• Therapeutic Vascular Remodeling

  Controlled vascular growth-factor delivery is being paired with pathway-directed remodeling to improve tissue repair and reproductive or neurologic outcomes. VEGF, FGF2 and PDGF hydrogels aim to increase microvascular density after myocardial infarction, while ERβ–ANGPT2 signaling is linked to decidual vascular remodeling in recurrent spontaneous abortion. In cerebral ischemia, Danshen-Chuanxiong is associated with carnitine metabolism and CPT1/HIF-1α activation. The field is moving toward context-specific control of vessel formation rather than nonspecific growth-factor exposure.

  4 papers · 44.4%

• Immunoangiogenic Cancer Therapy

  Antiangiogenic therapy is increasingly being paired with immune activation, checkpoint blockade and tumor-directed metabolic stress. Lenvatinib with PD-L1 inhibition is discussed in liver transplantation, while sunitinib delivered in a pH-responsive hydrogel is coupled to cuproptosis and immune reprogramming in clear cell renal carcinoma. Lung adenocarcinoma work similarly seeks to synchronize vascular control with CD4+ T-cell antitumor immunity and clinical translation. Functional imaging and treatment context remain important for judging whether these combinations improve tumor control.

  3 papers · 33.3%

• Anticancer Cell-Targeting Strategies

  Anticancer cell-targeting work centers on apoptosis, proliferation and migration rather than a single angiogenic mechanism. Combretastatin A-4–chalcone hybrids are being designed to inhibit tubulin polymerization and induce cytotoxicity with cell-cycle arrest. Menstrual blood stem cell-derived exosomes are instead evaluated for coordinated effects on apoptosis, migration and angiogenesis in breast cancer cells. The shared evidence remains exploratory, with no clear winner between direct cytotoxic chemistry and biologic modulation.

  2 papers · 22.2%